Search
  • Biohaven Pharmaceuticals

Migraines Can Impact a Child's Quality of Life

Chronic pediatric migraines often cause children and adolescents to miss both school and extracurricular activities. Hear 14-year old I’yyonce describe her experience with ongoing pediatric migraines.


Biohaven Pharmaceuticals is studying an investigational drug, to potentially treat migraines in the pediatric population. If you or your child, between 12 and 18 years of age, suffer from migraine for at least 6 months you may qualify. Learn more about our pediatric migraine study.

Recent Posts

See All